TSHA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Taysha Gene Therapies Inc (TSHA) is not a strong buy for a beginner, long-term investor at this moment. While there are positive catalysts such as hedge fund buying and favorable analyst ratings, the company's weak financial performance, lack of recent news, and technical indicators showing no clear upward momentum suggest that it is better to hold off on investing right now. The stock's pre-market decline and lack of strong trading signals further support a cautious approach.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 39.906, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its support level (S1: 4.499), with a pre-market price of 4.52, down 1.09%. This suggests limited immediate upside potential.
Hedge funds are buying aggressively, with a 649.63% increase in buying over the last quarter. Analysts have raised price targets to $11, citing optimism around the company's Rett syndrome study.
The company's financials are weak, with revenue dropping to zero in Q3 2025 and a net loss of -$32.73 million. No recent news or congress trading data is available, and the stock's short-term trend indicates a likelihood of further declines (-0.92% in the next week, -5.38% in the next month).
In Q3 2025, revenue dropped to $0 (-100% YoY), net income improved to -$32.73 million (+28.24% YoY), EPS fell to -0.09 (-10% YoY), and gross margin remained at 100%. The company is not generating revenue, which is a significant concern for long-term investors.
Analysts are optimistic, with Wells Fargo and Goldman Sachs both assigning price targets of $11 and highlighting the company's potential in its Rett syndrome study. However, these are speculative and contingent on the success of clinical trials.
